ZINFORO® Phase III Asia CAP study design¹:

• Phase III, prospective, multicentre, randomised, double-blind, comparative trial
   

• ​​​​​​​Multinational: China, Taiwan, South Korea, Vietnam and India

The Asia CAP study included adult patients with a diagnosis of CAP requiring hospitalisation and PORT risk Class III or IV.¹

*The primary objective was to assess the clinical cure rates at the TOC visit (8-15 days after the last dose) in the CE population; non-inferiority was defined as a lower limit of the 95% CI ≥–10% for the between-group difference. If this was achieved, the protocol stated that superiority would be concluded if the lower limit of the 95% CI ≥0%.¹

The safety profile of ZINFORO® 600 mg q12h was shown to be comparable with ceftriaxone 2 g every 24 hours, as expected for the cephalosporin class.¹

CAP, community-acquired pneumonia; CE, clinically evaluable; CI, confidence interval; PORT, Pneumonia Patient Outcomes Research Team; q12h, every 12 hours; q24h, every 24 hours; TOC, test of cure.^{​​​​​}